Cargando…

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition

Treatment with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the default treatment for muscle-invasive bladder cancer (BC). However, with the encouraging results of immune checkpoint inhibitiors (ICI) directed against PD-1/PD-L1 and CTLA-4 in recent years, the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dorp, Jeroen, van der Heijden, Michiel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505825/ https://www.ncbi.nlm.nih.gov/pubmed/37727793 http://dx.doi.org/10.3389/fimmu.2023.1235884

Ejemplares similares

Immune Checkpoint Inhibition in Head and Neck Cancer
por: Forster, Martin David, et al.
Publicado: (2018)

Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
por: Zheng, Guoxing, et al.
Publicado: (2023)

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
por: Engelsen, Agnete S. T., et al.
Publicado: (2022)

The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
por: Varricchi, Gilda, et al.
Publicado: (2019)

Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy
por: Chen, Xingyu, et al.
Publicado: (2021)

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
por: Bidnur, S., et al.
Publicado: (2016)

TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer
por: Looney, Timothy John, et al.
Publicado: (2020)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
por: Georganaki, Maria, et al.
Publicado: (2018)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

PSGL-1 Immune Checkpoint Inhibition for CD4(+) T Cell Cancer Immunotherapy
por: DeRogatis, Julia M., et al.
Publicado: (2021)

Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions
por: Chen, Jiao-Ting, et al.
Publicado: (2023)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition
por: de Joode, K., et al.
Publicado: (2021)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition
por: Donlon, Noel E., et al.
Publicado: (2022)

Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy
por: Bazhin, Alexandr V., et al.
Publicado: (2018)

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
por: Jiang, Jiehan, et al.
Publicado: (2021)

Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer
por: Cui, Yu, et al.
Publicado: (2023)

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness
por: Ursino, Chiara, et al.
Publicado: (2023)

Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors
por: Eckert, Franziska, et al.
Publicado: (2019)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
por: Anzar, Irantzu, et al.
Publicado: (2023)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
por: Gibellini, Lara, et al.
Publicado: (2020)

Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer
por: Pagliarulo, Fabio, et al.
Publicado: (2022)

Dynamic evaluation of blood immune cells predictive of response to immune checkpoint inhibitors in NSCLC by multicolor spectrum flow cytometry
por: Ma, Weijie, et al.
Publicado: (2023)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

The Role of NcRNAs to Regulate Immune Checkpoints in Cancer
por: Jiang, Yicun, et al.
Publicado: (2022)

The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
por: van Dijk, Nick, et al.
Publicado: (2021)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
por: Elia, Angela Rita, et al.
Publicado: (2018)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
por: Kabacaoglu, Derya, et al.
Publicado: (2018)

Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma
por: Pan, Yi-Ru, et al.
Publicado: (2022)

Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier
por: Frederico, Stephen C., et al.
Publicado: (2023)

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
por: Tao, Shengwei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n443tp4j10ds3qod1vdfa258av